Cagrilintide Research for Obesity
An evidence-based overview of research examining Cagrilintide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Cagrilintide has shown significant weight loss efficacy in clinical trials. Phase 2 monotherapy achieved -10.8% weight loss at 26 weeks. When combined with semaglutide (CagriSema), Phase 1b/2 data showed -15.6% to -17.1% weight loss. The Phase 3 REDEFINE 1 trial reported -20.4% weight loss with the combination versus -3.0% placebo at 68 weeks using a treatment-regimen estimand. Its cagrilintide-only arm was reported by Novo as -11.8% versus -2.3% placebo using an on-treatment estimand. Khan et al. (PMID 42608559) reports pooled kilogram differences for CagriSema versus cagrilintide monotherapy (−9.24 kg) and versus placebo (−13.99 kg), not a monotherapy percent estimand.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.